Trial Profile
Randomized, double blind, active-controlled, parallel study to analyse effects of the combination of aliskiren and valsartan on the vascular structure and function of retinal vessels.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Valsartan (Primary)
- Indications Essential hypertension
- Focus Pharmacodynamics
- Acronyms ARTS
- 02 Apr 2022 Status changed from recruiting to completed.
- 19 Jul 2011 New trial record